US 12,090,163 B2
Pharmaceutical compositions
Geena Malhotra, Mumbai (IN); Kalpana Joshi, Thane (IN); Jeevan Ghosalkar, Dombivali (IN); Atul Daroi, Thane (IN); and Siddharth Agrawal, Nagpur (IN)
Assigned to CIPLA LIMITED, Mumbai (IN)
Appl. No. 16/626,502
Filed by CIPLA LIMITED, Mumbai (IN)
PCT Filed Jun. 29, 2018, PCT No. PCT/IN2018/050427
§ 371(c)(1), (2) Date Dec. 24, 2019,
PCT Pub. No. WO2019/003251, PCT Pub. Date Jan. 3, 2019.
Claims priority of application No. 201721023142 (IN), filed on Jun. 30, 2017.
Prior Publication US 2020/0113919 A1, Apr. 16, 2020
Int. Cl. A61K 31/675 (2006.01); A61P 31/18 (2006.01); A61P 31/22 (2006.01); A61K 45/06 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 31/675 (2013.01) [A61P 31/18 (2018.01); A61P 31/22 (2018.01); A61K 45/06 (2013.01); B82Y 5/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising ((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)oxy)methyl pivalate in the form of a fumarate salt or a pharmaceutically acceptable derivative thereof in an amount from about 2% to about 80% of the composition, one or more pharmaceutically acceptable excipients, and a therapeutic agent selected from the group consisting of: emtricitabine, efavirenz, nevirapine, darunavir, atazanavir, cobicistat, dolutegravir, elvitegravir, raltegravir, and any combination thereof.